Sabrina Roussel

Dr. Sabrina Roussel

Pharmacy, Université Laval, Québec, Canada
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
IVIara Maíra de Oliveira Viana
Iara Maíra de Oliveira Viana
SRSabrina Roussel
Sabrina Roussel
JDJoan Defrêne
Joan Defrêne
ELEliana Martins Lima
Eliana Martins Lima
FBFrédéric Barabé
Frédéric Barabé
NBNicolas Bertrand
Nicolas Bertrand
Since the commercialization of the first liposomes used for drug delivery, Doxil/Caelyx® and Myocet, tremendous progress has been made in understanding interactions between nanomedicines and biological systems. Fundamental work at the interface of engineering and medicine has allowed nanomedicines to deliver therapeutic small molecules and nucleic acids more efficiently. While nanomedicines are used in oncology for immunotherapy or to deliver combinations of cytotoxics, the clinical successes of gene silencing approaches like patisiran lipid complexes (Onpattro®) have paved the way for a variety of therapies beyond cancer. In parallel, the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the potential of mRNA vaccines to develop immunization strategies at unprecedented speed. To rationally design therapeutic and vaccines, chemists, materials scientists, and drug delivery experts need to better understand how nanotechnologies interact with the immune system. This review presents a comprehensive overview of the innate and adaptative immune systems and emphasizes the intricate mechanisms through which nanomedicines interact with these biological functions.

25 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SRSabrina Roussel
Sabrina Roussel
PGPhilippe Grenier
Philippe Grenier
VCValérie Chénard
Valérie Chénard
NBNicolas Bertrand
Nicolas Bertrand
Fluorescent labelling is commonly used to monitor the biodistribution of nanomedicines. However, meaningful interpretation of the results requires that the fluorescent label remains attached to the nanomedicine. In this work, we explore the stability of three fluorophores (BODIPY650, Cyanine 5 and AZ647) attached to polymeric hydrophobic biodegradable anchors. Using dual-labelled poly(ethylene glycol)-b-poly(lactic acid) (PEG-PLA) nanoparticles that are both radioactive and fluorescent, we investigated how the properties of the fluorophores impact the stability of the labelling in vitro and in vivo. Results suggest that the more hydrophilic dye (AZ647) is released faster from nanoparticles, and that this instability results in misinterpretation of in vivo data. While hydrophobic dyes are likely more suitable to track nanoparticles in biological environments, quenching of the fluorescence inside the nanoparticles can also introduce artefacts. Altogether, this work raises awareness about the importance of stable labelling methods when investigating the biological fate of nanomedicines.

17 November 2026 in RSC Pharmaceutics
Verified
Journal Article
Open access
SRSabrina Roussel
Sabrina Roussel
EAEce Ates
Ece Ates
Ryan DonnellyRyan Donnelly
Ryan Donnelly
NBNicolas Bertrand
Nicolas Bertrand
Polyethylene glycol- b -polylactic acid (PEG–PLA) nanoparticles were incorporated into polyvinylpyrrolidone/polyvinyl alcohol (PVP/PVA) microneedles. When injected intradermally, the nanoparticles triggered the production of anti-PEG IgM antibodies.